| Literature DB >> 32126969 |
Senthil Packiasabapathy1, Varesh Prasad2,3, Valluvan Rangasamy1, David Popok4, Xinling Xu1, Victor Novack4, Balachundhar Subramaniam5,6.
Abstract
BACKGROUND: Recent literature suggests a significant association between blood pressure variability (BPV) and postoperative outcomes after cardiac surgery. However, its outcome prediction ability remains unclear. Current prediction models use static preoperative patient factors. We explored the ability of Poincaré plots and coefficient of variation (CV) by measuring intraoperative BPV in predicting adverse outcomes.Entities:
Keywords: BP variability; Cardiac surgery; Coefficient of variation; Poincaré plot; STS risk score
Mesh:
Year: 2020 PMID: 32126969 PMCID: PMC7055104 DOI: 10.1186/s12871-020-00972-5
Source DB: PubMed Journal: BMC Anesthesiol ISSN: 1471-2253 Impact factor: 2.217
Fig. 1Flow chart presenting patient selection and analysisa. a Figure reproduced from Jinadasa SP et al. Anesth. Analg. 2018;127:832–9. Copyright© 2018 International Anesthesia Research Society
Baseline Characteristics of patients stratified by mortality and renal failurea
| Baseline Characteristics | Entire Cohort | Survivors | Non-Survivors | No Renal Failure | Renal Failure | ||
|---|---|---|---|---|---|---|---|
| Age, | 68 (60, 76) | 68 (60, 76) | 72 (62, 78) | 0.002* | 68 (60, 76) | 73 (59, 81) | 0.03 |
| Male genderc | 2565 (69.57) | 2505 (69.82) | 60 (60.61) | 0.049* | 2496 (69.68) | 69 (65.71) | 0.38 |
| Baseline Comorbidities | |||||||
| Hypertension | 2900 (78.65) | 2817 (78.51) | 83 (83.84) | 0.20 | 2808 (78.39) | 92 (87.62) | 0.02* |
| Congestive Heart Failure | 1024 (27.77) | 969 (27.01) | 55 (55.56) | < 0.0001* | 967 (27.00) | 57 (54.29) | < 0.0001* |
| Cerebrovascular Disease | 550 (14.92) | 521 (14.52) | 29 (29.29) | < 0.0001* | 521 (14.54) | 29 (27.62) | 0.0002* |
| Dyslipidaemia | 2702 (73.28) | 2635 (73.44) | 67 (67.68) | 0.20 | 2631 (73.45) | 71 (67.62) | 0.18 |
| Previous Myocardial Infarction | 1120 (30.38) | 1073 (29.91) | 47 (47.47) | 0.0002* | 1082 (30.21) | 38 (36.19) | 0.19 |
| Diabetes | 1154 (31.30) | 1116 (31.10) | 38 (38.38) | 0.12 | 1116 (31.16) | 38 (36.19) | 0.27 |
| Chronic Lung Disease | 499 (13.53) | 473 (13.18) | 26 (26.26) | 0.0002* | 476 (13.29) | 23 (21.90) | 0.01* |
| Dialysis | 84 (6.27) | 80 (2.23) | 4 (4.04) | 0.29 | 0 | 84 | 0.18 |
| LVEF† | 52.5 (50.0, 60.0) | 52.5 (50.0, 60.0) | 52.5 (50.0, 56.25) | 0.18 | 52.5 (50.0, 60.0) | 52.5 (50.0, 57.5) | 0.17 |
| Preoperative Medicationsc | |||||||
| Aspirin | 2984 (80.93) | 2904 (80.94) | 80 (80.81) | 0.97 | 2900 (80.96) | 84 (80.00) | 0.81 |
| β-Blockers | 2714 (73.61) | 2643 (73.66) | 71 (71.72) | 0.66 | 2640 (73.7) | 74 (70.48) | 0.46 |
| ACE-I or ARBS | 1621 (43.97) | 1579 (44.01) | 42 (42.42) | 0.75 | 1575 (43.97) | 46 (43.81) | 0.97 |
| Lipid Lowering | 2782 (75.45) | 2713 (75.61) | 69 (69.70) | 0.18 | 2706 (75.54) | 76 (72.38) | 0.46 |
| Steroids | 146 (3.96) | 135 (3.76) | 11 (11.11) | 0.002* | 139 (3.88) | 7 (6.67) | 0.19 |
| Intraoperative vasopressor-inotropes. | 0.63 (0.30, 1.15) | 0.63 (0.30, 1.12) | 0.99 (0.29, 3.03) | 0.01 | 0.63 (0.31, 1.13) | 0.69 (0.13, 2.75) | 0.36 |
| Surgical Characteristics | |||||||
| Surgery Type | |||||||
| CABG | 1751 (47.49) | 1722 (47.99) | 29 (29.29) | < 0.0001* | 1725 (48.16) | 26 (24.76) | < 0.0001* |
| CABG + Valve | 725 (19.66) | 687 (19.15) | 38 (38.38) | 689 (19.24) | 36 (34.29) | ||
| Valved | 1097 (29.75) | 1076 (29.99) | 21 (21.21) | 1059 (29.56) | 38 (36.19) | ||
| Other | 114 (3.09) | 103 (2.87) | 11 (11.11) | 109 (3.04) | 5 (4.76) | ||
| STS Risk Score for Morbidity and Mortalityb | 0.01 (0.01, 0.03) | 0.01 (0.01, 0.03) | 0.06 (0.02, 0.11) | < 0.0001* | 0.01 (0.01, 0.03) | 0.05 (0.02, 0.11) | < 0.0001* |
| STS Predicted Risk Score for Renal Failureb | 0.03 (0.01, 0.06) | 0.03 (0.01, 0.06) | 0.09 (0.04, 0.17) | < 0.0001* | 0.03 (0.01, 0.06) | 0.11 (0.04, 0.21) | < 0.0001* |
| Bypass Period Time, | |||||||
| Pre-Bypass | 126.0 (104.3, 148.8) | 125.8 (104.3, 148.5) | 141.5 (108.3, 170.8) | 0.004* | 125.8 (104.3, 148.5) | 134.8 (108.3, 161.8) | 0.02* |
| Bypass | 79.3 (63.8, 100.0) | 79.0 (63.7, 99.0) | 105.8 (75.2, 141.3) | < 0.0001* | 79.0 (63.5, 99.0) | 102.5 (75.8, 133.7) | < 0.0001* |
| Post-Bypass | 76.5 (65.8, 90.8) | 76.3 (65.8, 89.8) | 95.5 (79.5, 135.5) | < 0.0001* | 76.3 (65.8, 90.0) | 92.3 (74.8, 120.8) | < 0.0001* |
| Cross Clamp Time, | 71.0 (56.0, 91.0) | 71.0 (56.0, 91.0) | 93.0 (65.0, 129.0) | < 0.0001* | 71.0 (56.0, 91.0) | 94.5 (67.5, 120.0) | < 0.0001* |
*Statistically significant at a level of significance of P < 0.05,
a Figure reproduced from Jinadasa SP et al. Anesth. Analg. 2018;127:832–9. Copyright© 2018 International Anesthesia Research Society
b Median [interquartile range]. c Number and %
d Type of valve surgery: Aortic, Mitral, Tricuspid, Aortic + Mitral valve replacement surgeries
ACE-I angiotensin-converting enzyme inhibitor, ARBs angiotensin receptor blockers, STS Society of Thoracic Surgery, CABG coronary artery bypass graft
Blood Pressure and Coefficient of Variation of patients stratified by mortality and renal failurea
| Exposure measures | Entire Cohort | Survivors | Non-Survivors | No Renal Failure | Renal Failure | ||
|---|---|---|---|---|---|---|---|
| Blood Pressureb | |||||||
| 106 (102, 111) | 106 (102, 111) | 102 (97, 109) | 0.0002* | 106 (102, 111) | 103 (97, 109) | 0.001* | |
| Pre-Bypass | 111 (105, 118) | 111.5 (105, 118) | 110 (101, 117) | 0.045 | 111.5 (105, 118) | 110 (103, 116) | 0.046 |
| Post-Bypass | 100 (95, 105) | 100 (95, 105) | 97 (88, 103) | 0.0002* | 100 (95, 105) | 96 (91, 104) | 0.001* |
| 70 (67, 73) | 70 (67, 73) | 66 (62, 71) | < 0.0001* | 70 (67, 73) | 65 (62, 69) | < 0.0001* | |
| Pre-Bypass | 78 (73, 83) | 78 (73, 83) | 75 (67, 80) | < 0.0001* | 78 (73, 83) | 75 (66, 80) | < 0.0001* |
| Bypass | 57 (53, 62) | 57 (53, 62) | 58 (51, 64) | 0.97 | 57 (53, 62) | 57 (53, 63) | 0.92 |
| Post-Bypass | 70 (66, 74) | 70 (66, 74) | 66 (62, 71) | < 0.0001* | 70 (66, 74) | 65 (61, 69.5) | < 0.0001* |
| Coefficient of Variationb | |||||||
| 0.21 (0.19, 0.25) | 0.21 (0.19, 0.24) | 0.24 (0.21, 0.27) | < 0.0001* | 0.21 (0.19, 0.24) | 0.23 (0.21, 0.27) | < 0.0001* | |
| Pre-Bypass | 0.20 (0.17, 0.23) | 0.20 (0.17, 0.23) | 0.20 (0.17, 0.25) | 0.16 | 0.20 (0.17, 0.23) | 0.21 (0.18, 0.25) | 0.03* |
| Post-Bypass | 0.18 (0.15, 0.22) | 0.18 (0.15, 0.22) | 0.21 (0.17, 0.24) | < 0.0001* | 0.18 (0.15, 0.22) | 0.20 (0.17, 0.25) | 0.001* |
| 0.29 (0.25, 0.37) | 0.29 (0.25, 0.37) | 0.31 (0.25, 0.39) | 0.26 | 0.29 (0.25, 0.37) | 0.30 (0.24, 0.38) | 0.54 | |
| Pre-Bypass | 0.27 (0.22, 0.38) | 0.27 (0.22, 0.38) | 0.27 (0.22, 0.42) | 0.50 | 0.27 (0.22, 0.38) | 0.28 (0.23, 0.40) | 0.46 |
| Bypass | 0.15 (0.13, 0.18) | 0.15 (0.13, 0.18) | 0.15 (0.12, 0.21) | 0.82 | 0.15 (0.13, 0.18) | 0.15 (0.12, 0.20) | 0.98 |
| Post-Bypass | 0.22 (0.17, 0.27) | 0.22 (0.17, 0.27) | 0.24 (0.19, 0.29) | 0.02* | 0.22 (0.17, 0.27) | 0.23 (0.19, 0.28) | 0.10 |
a Figure reproduced from Jinadasa SP et al. Anesth. Analg. 2018;127:832–9. Copyright© 2018 International Anesthesia Research Society
b Median [interquartile range]. *Statistically significant at a level of significance of P < 0.05
Fig. 2a Poincaré plot of a survivor, with the ellipse and derived parameters (SD1 and SD2) b Poincaré plot of a non-survivor, with the ellipse and derived parameters (SD1 and SD2). MAP– Mean Arterial Pressure at a data point on time series, MAP– Mean Arterial Pressure at a data point next on time series. SD1- minor semi-axis of the fitted ellipse, SD2- major semi-axis of the fitted ellipse
Poincare parameters (SD1, SD2) of SBP and MAP, stratified by mortality and renal failure
| SD1 (mmHg) | 4.43 (3.32, 6.58) | 4.54 (3.09, 6.53) | 0.27 | NA | NA | NA | 3.88 (2.92, 7.52) | 5.04 (3.00, 9.08) | 0.04* |
| SD2 (mmHg) | 28.46 (23.88, 34.08) | 28.72 (23.51, 32.26) | 0.58 | NA | NA | NA | 23.51 (19.77, 27.59) | 25.41 (20.17, 29.94) | < 0.01* |
| SD1/SD2 | 0.15 (0.12, 0.22) | 0.15 (0.11, 0.21) | 0.068 | NA | NA | NA | 0.18 (0.13, 0.29) | 0.2 (0.14, 0.35) | 0.47 |
| SD1 (mmHg) | 8.11 (5.64, 10.43) | 7.49 (4.77, 9.73) | 0.51 | 2.78 (2.23, 3.48) | 2.42 (1.88, 3.02) | < 0.01 | 8.45 (5.37, 11.15) | 8.29 (6.18, 10.91) | 0.25 |
| SD2 (mmHg) | 21.68 (18.24, 26.32) | 21.44 (16.81, 26.89) | 0.78 | 12.04 (9.82, 14.75) | 12.13 (9.28, 14.95) | 0.88 | 17.34 (14.24, 20.99) | 16.92 (13.49, 20.20) | 0.02* |
| SD1/SD2 | 0.35 (0.23, 0.47) | 0.33 (0.20, 0.42) | 0.25 | 0.24 (0.19, 0.29) | 0.21 (0.16, 0.27) | < 0.01 | 0.46 (0.31, 0.60) | 0.50 (0.37, 0.64) | 0.93 |
| SD1 (mmHg) | 4.43 (3.32, 6.58) | 4.36 (3.03, 6.52) | 0.39 | NA | NA | NA | 3.88 (2.92, 7.53) | 4.84 (3.00, 8.95) | 0.09 |
| SD2 (mmHg) | 28.46 (23.88, 34.08) | 28.72 (23.43, 35.02) | 0.56 | NA | NA | NA | 23.50 (19.77, 27.59) | 25.4 (20.35, 29.90) | 0.02* |
| SD1/SD2 | 0.15 (0.12, 0.22) | 0.15 (0.11, 0.21) | 0.12 | NA | NA | NA | 0.18 (0.13, 0.29) | 0.19 (0.14, 0.35) | 0.23 |
| SD1 (mmHg) | 8.11 (5.64, 10.43) | 7.49 (4.77, 9.73) | 0.07 | 2.78 (2.23, 3.48) | 2.44 (1.89, 3.05) | < 0.01 | 8.45 (5.39, 11.15) | 8.29 (5.93, 10.86) | 0.95 |
| SD2 (mmHg) | 21.68 (18.24, 26.32) | 21.44 (16.67, 26.57) | 0.53 | 12.04 (9.81, 14.74) | 12.13 (9.37, 14.82) | 0.83 | 17.35 (14.24, 20.99) | 16.84 (13.42, 20.19) | 0.16 |
| SD1/SD2 | 0.35 (0.23, 0.47) | 0.33 (0.19, 0.42) | 0.07 | 0.24 (0.19, 0.29) | 0.21 (0.16, 0.27) | < 0.01 | 0.46 (0.31, 0.60) | 0.5 (0.36, 0.64) | 0.06 |
*Statistically significant at a level of significance of P < 0.05, Median [interquartile range]
NA Systolic Blood Pressure is not recorded during bypass due to non-pulsatile flow, SD1 Short term variability, SD2 Long term variability, SBP systolic blood pressure, MAP Mean arterial pressure
Univariable unadjusted models: BPV parameters
| Outcome: Mortality | Outcome: Renal Failure | |||
|---|---|---|---|---|
| Variable | C-statistic AUC (95% CI) | C-statistic AUC (95% CI) | ||
| Pre-Bypass CV | 0.541 (0.476–0.606) | 0.011* | 0.564 (0.504–0.623) | 0.012* |
| Post-Bypass CV | 0.621 (0.567–0.676) | < 0.001* | 0.599 (0.537–0.660) | < 0.001* |
| Pre-Bypass CV | 0.520 (0.459–0.582) | 0.127 | 0.522 (0.463–0.580) | 0.165 |
| Bypass CV | 0.494 (0.428–0.559) | 0.030* | 0.499 (0.438–0.561) | 0.085 |
| Post-Bypass CV | 0.570 (0.517–0.623) | 0.123 | 0.548 (0.493–0.602) | 0.181 |
| Pre-Bypass SD1 | 0.536 (0.470–0.602) | 0.699 | 0.538 (0.477–0.599) | 0.445 |
| Post-Bypass SD1 | 0.518 (0.458–0.578) | 0.548 | 0.513 (0.455–0.570) | 0.856 |
| Pre-Bypass SD1 | 0.490 (0.427–0.552) | 0.615 | 0.546 (0.484–0.608) | 0.368 |
| Bypass SD1 | 0.546 (0.484–0.608) | 0.425 | 0.480 (0.419–0.541) | 0.256 |
| Post-Bypass SD1 | 0.539 (0.482–0.595) | 0.401 | 0.535 (0.480–0.591) | 0.088 |
| Pre-Bypass SD2 | 0.544 (0.479 to 0.610) | 0.013* | 0.479 (0.416–0.541) | 0.124 |
| Post-Bypass SD2 | 0.624 (0.563–0.685) | < 0.001* | 0.584 (0.520–0.649) | < 0.001* |
| Pre-Bypass SD2 | 0.530 (0.467–0.592) | 0.015* | 0.500 (0.436–0.564) | 0.982 |
| Bypass SD2 | 0.501 (0.434–0.569) | 0.203 | 0.518 (0.455–0.580) | 0.015* |
| Post-Bypass SD2 | 0.580 (0.524–0.637) | 0.030* | 0.491 (0.434–0.547) | 0.360 |
*Statistically significant at a level of significance of P < 0.05; BPV blood pressure variability, AUC Area under the receiver operating curve, CI 95% Confidence Interval, CV Coefficient of Variation, SD1 Short term variability, SD2 Long term variability
Predictive ability of STS risk alone for mortality and renal failure
| Outcomes | C-statistic |
|---|---|
| AUC* (CI) | |
| 0.766 (0.719–0.814) | |
| 0.734 (0.689–0.780) |
*AUC Area under the receiver operating curve, CI 95% Confidence Interval, STS society of thoracic surgeons
Multivariable adjusted model: BP variability parameters adjusted to age, surgery category, STS risk score, and intraoperative vasopressor dose
| Outcome: Mortality | Outcome: Renal Failure | |||
|---|---|---|---|---|
| Variable | C-statistic AUC (95% CI) | C-statistic AUC (95% CI) | ||
| Pre-Bypass CV | 0.769 (0.723–0.816) | 0.109 | 0.739 (0.694–0.784) | 0.177 |
| Post-Bypass CV | 0.780 (0.736–0.823) | 0.008* | 0.745 (0.699–0.792) | 0.002* |
| Pre-Bypass CV | 0.766 (0.719–0.814) | 0.870 | 0.734 (0.689–0.780) | 0.774 |
| Bypass CV | 0.766 (0.718–0.814) | 0.868 | 0.734 (0.688–0.780) | 0.634 |
| Post-Bypass CV | 0.768 (0.721–0.815) | 0.246 | 0.736 (0.690–0.783) | 0.270 |
| Pre-Bypass SD1 | 0.762 (0.719–0.814) | 0.993 | 0.735 (0.689–0.781) | 0.553 |
| Post-Bypass SD1 | 0.767 (0.720–0.814) | 0.312 | 0.734 (0.689–0.780) | 0.498 |
| Pre-Bypass SD1 | 0.766 (0.719–0.814) | 0.946 | 0.731 (0.685–0.778) | 0.121 |
| Bypass SD1 | 0.770 (0.724–0.817) | 0.238 | 0.732 (0.687–0.778) | 0.394 |
| Post-Bypass SD1 | 0.768 (0.720–0.815) | 0.231 | 0.731 (0.684–0.779) | 0.168 |
| Pre-Bypass SD2 | 0.776 (0.732–0.820) | 0.016 | 0.737 (0.692–0.783) | 0.169 |
| Post-Bypass SD2 | 0.789 (0.746–0.832) | < 0.001* | 0.741 (0.694–0.788) | 0.004* |
| Pre-Bypass SD2 | 0.768 (0.722–0.815) | 0.094 | 0.731 (0.685–0.777) | 0.405 |
| Bypass SD2 | 0.765 (0.718–0.813) | 0.708 | 0.730 (0.684–0.777) | 0.067 |
| Post-Bypass SD2 | 0.772 (0.725–0.819) | 0.046* | 0.731 (0.684–0.778) | 0.369 |
*Statistically significant at a level of significance of P < 0.05, STS Society of Thoracic Surgeons, AUC Area under the receiver operating curve, CI 95% Confidence Interval, CV Coefficient of Variation, SD1 Short term variability, SD2 Long term variability